You can help us support people living with HIV
The HIV Netherlands Australia Thailand Research Collaboration
Wish Your Love
Art Care
  • The HIV Netherlands Australia Thailand Research Collaboration
  • HIV-NAT Clinical Research
  • HIV-NAT Laboratory
  • HIV-NAT Pharmaceutical
The HIV Netherlands Australia Thailand Research Collaboration. (HIV-NAT)
HIV-NAT is affiliated with The Thai Red Cross AIDS Research Centre in Bangkok, Thailand, with the Kirby Institute for infection and immunity in society in Sydney, Australia, and with the Amsterdam Institute for Global Health and Development in Amsterdam, The Netherlands. Since 1996 our centre has been conducting clinical research in HIV, meeting international standards, and gaining vast experience in the coordination of multicentre trials in Thailand.
Conference & Training
Bangkok International Symposium on HIV Medicine
One of the best HIV medicine conferences in Asia Pacific, the Bangkok International Symposium brings together experts in the HIV field from all over the world. The next Symposium will take place from 13-15 January 2016.
HIV-NAT Mini Symposium
The Symposium Series training workshops are centered on care management and treatment for people living with HIV/AIDS. The purpose of the training workshop is to provide in-depth knowledge on HIV care and treatment to medical doctors, nurses, pharmacists and healthcare practitioners. The training workshops are conducted in Thai.
In 2014 HIV-NAT organized various trainings to provide knowledge and information on clinical research and HIV infection management to health care professionals in Thailand and around the world. These trainings include:
Upcoming Events
  • 6 August 2015
    In-service lecture 2/2558 (Acute HIV infection & HIV cure research) by Dr. Jintanat
  • 13-15 Jan 2016
    The 18th Bangkok International Symposium on HIV Medicine
Journal
Journal of Virus Eradication Volumn 1 Issue 2
  • Wilaisakditipakorn, Tanaporn; Vilaisaktipakorn, Pitchamol; Bunupuradah, Torsak; Puthanakit, Thanyawee. A slow progressor HIV-infected boy developed quadriplegia with evidence of Epstein-Barr virus associated smooth muscle tumor of cervical spinal cord. BMJ Case Reports
  • Gary Maartens, Graeme Meintjes. Lower-dose efavirenz: what is needed before implementation?. Lancet Infect Dis 2015.
  • ENCORE1 Study Group. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis 2015.
The HIV Netherland Australia Thailand Research Collaboration
Tel.: +(662) 652 3040, Fax: +(662) 252 5779
© Copyright 2014 HIV-NAT. All Rights Reserved.